News

https://www.sep.benfranklin.org/news/ben-franklin-healthcare-investments-1-3-million-in-four-companies/ Ben Franklin Healthcare Investments continues support of SFA Therapeutics with additional investment. The fund has invested in 4 companies in the southeast Pennsylvania region and continues to be the Philadelphia regions's "Partner with a Purpose" SFA Therapeutics is based in Jenkintown, Montgomery county.   Contacts: INVESTORS Mike Moyer LifeSci Advisors mmoyer@lifesciadvisors.com COMPANY Ira C. Spector, PhD CEO SFA Therapeutics, Inc. iraspector@sfatherapeutics.com   Source: SFA Therapeutics, Inc. ...

SFA-002 Updated Extension Data Showing 92% PASI 50 and 72% PASI 75 $4.5 Million Bridge Financing led by North South Ventures Composition of Matter patent which covers over 40 potential disease indications for SFA-002   JENKINTOWN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- SFA Therapeutics, a clinical-stage biotech using a first-in-class immuno-modulation technology platform, is pleased to announce the completion of a bridge financing of $4.5 million, led...

JENKINTOWN, Pa., Aug. 14, 2023 (GLOBE NEWSWIRE) -- SFA Therapeutics, a clinical-stage biotech using a first-in-class immuno-modulation technology platform, announced positive results from their SFA-002 Phase 1b cohort 1 clinical trial. SFA’s oral pill SFA-002 has the potential to be disease-modifying, with durable responses and an excellent safety profile. SFA-002 simultaneously acts on multiple therapeutic pathways, unlike other drugs on the market which target a single...

Abstract Cancer is a multi-step process that can be viewed as a cellular and immunological shift away from homeostasis in response to selected infectious agents, mutations, diet, and environmental carcinogens. Homeostasis, which contributes importantly to the definition of “health,” is maintained, in part by the production of short-chain fatty acids (SCFAs), which are metabolites of specific gut bacteria. Alteration in the composition of gut bacteria, or...

Med Tech Gurus Developing The Next Big Thing Ira Spector Co-Founder & CEO of SFA Therapeutics delivers a master class in innovation and new product development. Ira walks us through the best practices of a licensing deal with a university and tell us “don’t be afraid to walk away”. Ira doesn’t stop there, he provides insights into designing elegant experiments and why that is so important in product development. He also...

PODCASTTreat Disease, Not the SymptomsIn this podcast, Dr. Ira Spector discusses how his career journey has epitomized the ability to solve problems, which is essentially the role of drug development. It has also led to the formation and strategic approach to his company’s early-stage clinical trials for using the microbiome to address chronic inflammatory diseases.Published on: March 7, 2023https://soundcloud.com/act-magazine/treat-disease-not-the-symptoms...

PROFILEA biotech CEO’s favorite ‘F’ wordAt SFA Therapeutics, patients are the “focus” of Ira Spector’s approach to changing the course of autoimmune disease.Published Jan. 26, 2023Read Ira Spector's PharmaVoice Profile ...

READ MORE...

SFA Therapeutics will begin testing of SFA001 in a Phase 1 exploratory trial at Einstein Hospital in Philadelphia 1Q 2023 Dr Manisha Verma MD, MPH to act as principal investigator SFA Therapeutics to test its novel anti-inflamaatory compound, SFA001 in NASH patients. SFA001 is a powerful microbiome derived orally active small molecule has been shown to greatly reduce chronic inflammation. Chronic inflammation leads to the activation of...

Tales From the 2022 Biotech VC Fundraising Trail After the bonanza of 2021, life-sciences entrepreneurs reset their expectations as financing contracted SFA Therapeutics CEO & Co-Founder, Ira Spector, PhD discusses Startup Biotech funding in The Wall Street Journal Wall Street Journal article titled   'Biotech Startup Fundraising Fell in 2022.'by Brian Gormley in the December 23, 2022, print edition. ...